SCHEMBL14969012

SCHEMBL14969012

CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N/Nc1cccc(Br)c1O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.37
KMT2A Q03164 7/20 0.37
MAPT P10636 6/20 0.36
ALDH1A1 P00352 5/20 0.36
L3MBTL1 Q9Y468 4/20 0.36
GAA P10253 3/20 0.36
HPGD P15428 2/20 0.36
PSMD14 O00487 1/20 0.36
KDM4E B2RXH2 3/20 0.35
MAOB P27338 1/20 0.34
TDP1 Q9NUW8 2/20 0.33
POLB P06746 2/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
CASP6 P55212 1/20 0.32
ATM Q13315 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
KAT8 Q9H7Z6 1/20 0.31
AMY1A P0DUB6 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31415058 1.00 MEN1 (0.37) MEN1KMT2AMAPTALDH1A1L3MBTL1
SCHEMBL14966103 1.00 MEN1 (0.37) MEN1KMT2AMAPTALDH1A1L3MBTL1
SCHEMBL16596970 1.00 MEN1 (0.37) MEN1KMT2AMAPTALDH1A1L3MBTL1
SCHEMBL24297214 0.89 ALDH1A1 (0.36) MEN1KMT2AMAPTALDH1A1L3MBTL1
SCHEMBL16596969 0.86 MEN1 (0.39) MEN1KMT2AMAPTALDH1A1L3MBTL1
SCHEMBL14966026 0.86 MEN1 (0.39) MEN1KMT2AMAPTALDH1A1L3MBTL1
SCHEMBL14968879 0.86 MEN1 (0.39) MEN1KMT2AMAPTALDH1A1L3MBTL1
SCHEMBL30871812 0.85 MEN1 (0.38) MEN1KMT2AMAPTALDH1A1L3MBTL1
SCHEMBL31555294 0.85 MEN1 (0.38) MEN1KMT2AMAPTALDH1A1L3MBTL1
SCHEMBL1742069 0.85 MEN1 (0.38) MEN1KMT2AMAPTALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9440927-B2 Process for preparation of substituted 3'-hydroazino-diphenyl-3-carboxylic acid compounds GLENMARK PHARMACEUTICALS LIMITED (IN) 2016-09-13 US disclosed
US-20150087845-A1 PROCESS FOR PREPARATION OF SUBSTITUTED 3'-HYDROAZINO-DIPHENYL-3-CARBOXYLIC ACID COMPOUNDS GLENMARK GENERICS LIMITED (IN) 2015-03-26 US disclosed
EP-2755955-A2 PROCESS FOR PREPARATION OF SUBSTITUTED 3'-HYDRAZINO-BIPHENYL-3-CARBOXYLIC ACID COMPOUNDS Glenmark Generics Limited (IN) 2014-07-23 EP disclosed
WO-2013072921-A2 PROCESS FOR PREPARATION OF SUBSTITUTED 3'-HYDRAZINO-BIPHENYL-3-CARBOXYLIC ACID COMPOUNDS GLENMARK GENERICS LIMITED (IN) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150087845-A1 PROCESS FOR PREPARATION OF SUBSTITUTED 3'-HYDROAZINO-DIPHENYL-3-CARBOXYLIC ACID COMPOUNDS CYP3A5, UGT1A3, HPD MEN1 3749/4885KMT2A 702/4885MAPT 2533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.